Fetal cell-derived bio serum in cosmetic dermatology: Sources, bioactivity, and therapeutic potential

The emergence of bioserum derived from fetal cells is revolutionizing regenerative cosmetics by providing a bioactive, cell-free alternative to traditional anti-aging and skin repair treatments. This mini-review examines the scientific foundations, sources, production methods, and applications of bioserum from human fetal tissues, focusing on dermal fibroblasts, mesenchymal stem cells (MSCs), and embryonic stem cell (ESC) derivatives. These bioserums are rich in regenerative biomolecules like growth factors (EGF, FGF, TGF-β), cytokines, and exosomes, which work synergistically to improve dermal rejuvenation and promote scarless wound healing. Conditioned media from fetal dermal fibroblasts and MSCs obtained from the umbilical cord and placenta have gained attention for their efficacy and relatively favorable ethical profiles. In contrast, while ESC-derived bioserum shows strong regenerative potential, it faces ethical and regulatory challenges. The review also discusses production issues, safety concerns, and the commercialization status of fetal bioserum, along with emerging trends like synthetic mimetics and exosome delivery. Despite promising benefits, concerns about standardization, cost, and long-term safety require careful consideration. This article provides an overview for researchers and clinicians interested in the therapeutic potential of fetal cell-derived bioserum in advanced cosmeceutical science.